2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1091

Trends in Patient Physical Activity Before and After Primary Total Hip Arthroplasty
Abstract Number: 2649

Trends in US Arthroplasty Rates 1991-2005: Patients with Inflammatory Arthritis Continue to Require Joint Replacement
Abstract Number: 1014

Trimmed Analyses, a New Approach to the Analysis of Sharp Score Data in the Assessment of Progression in Patients with Rheumatoid Arthritis
Abstract Number: 2044

Trying to Improve Care: A Review of the Morbidity and Mortality Conference in the Division of Rheumotology
Abstract Number: 1788

TSLP Induces TNFα Production by CD1c Myeloid Dendritic Cells and Myeloid DC-Activated T Cells From Rheumatoid Arthritis Patients
Abstract Number: 1513

TSLP Receptor Deficiency Reduces IL-13 Expression and Prevents Fibrosis in Experimental Scleroderma
Abstract Number: 1516

TSLP Upregulation in Human SSc Skin and Induction of Overlapping Profibrotic Genes and Intracellular Signaling with IL-13 and TGFb
Abstract Number: 1278

Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 1416

Tumor Necrosis Factor Alpha Is Associated with Mood Disorders in Patients with Systemic Lupus Erythematosus
Abstract Number: 1702

Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Abstract Number: 1852

Tumour Necrosis Factor-Alpha Antagonists and Alopecia: A Case/Non-Case Study in a Nationwide Pharmacovigilance Database
Abstract Number: 592

Two Novel Diagnostic Biomarkers of Cartilage Degradation and Connective Tissue Inflammation Are Predictive of Disease Progression in Ankylosing Spondylitis
Abstract Number: 1271

Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
Abstract Number: 2290

Type I Interferon Associated Gene IRF7 in the Pathogenesis of Fibrosis in Systemic Sclerosis (SSc)
Abstract Number: 896

Tyro3, Axl, MerTK-Receptor Activation by Gas6 or Pros1 Gene Delivery, ameliorates Collagen-induced arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].